Effect of probucol on the oral bioavailability of cyclosporine A

European Journal of Pharmaceutical Sciences

Volumn 22, Issue 1, 2004, Pages 71-77

  Sugimoto, Koh Ichi ^a   Sudoh, Toshiaki ^a   Tsuruoka, Shuichi ^a   Yamamoto, Yoshihisa ^b   Maezono, Sachiko ^b   Watanabe, Yoshiteru ^b   Fujimura, Akio ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Bioavailability; Caco 2; Cyclosporine A; P glycoprotein; Probucol

Indexed keywords

ANTILIPEMIC AGENT; CYCLOSPORIN A; PROBUCOL;

ABSORPTION SPECTROSCOPY; ANIMAL EXPERIMENT; ARTICLE; CELL LINE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; DRUG TRANSPORT; HUMAN; HUMAN CELL; LIGHT ABSORPTION; MALE; NONHUMAN; PREMEDICATION; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT, ACTIVE; CACO-2 CELLS; CYCLOSPORINE; HUMANS; INTESTINAL ABSORPTION; MALE; P-GLYCOPROTEIN; PROBUCOL; RATS; RATS, WISTAR; SPECTROPHOTOMETRY, ULTRAVIOLET; TIME FACTORS;

EID: 2142660664     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2004.02.009     Document Type: Article

References (21)

1. Augustijns P.F., Bradshaw T.P., Gan L.S., Hendren R.W., Thakker D.R. Evidence for a polarized efflux system in CACO-2 cells capable of modulating cyclosporin A transport. Biochem. Biophys. Res. Commun. 197:1993;360-365
2. Cavet M.E., West M., Simmons N.L. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br. J. Pharmacol. 118:1996;1389-1396
3. Gallego C., Sanchez P., Planells C., Sanchez S., Monte E., Roma E., Sanchez J., Pallardo L.M. Interaction between probucol and cyclosporine in renal transplant patients. Ann. Pharmacotherap. 28:1994;940-943
4. Greiner B., Eichelbaum M., Fritz P., Kreichgauer H.P., von Richter O., Zundler J., Kroemer H.K. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 1041:1999;47-153
5. Hebert M.F., Fisher R.M., Marsh C.L., Dressler D., Bekersky I. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J. Clin. Pharmacol. 39:1999;91-96
6. Hunter J., Jepson M.A., Tsuruo T., Simmons N.L., Hirst B.H. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J. Biol. Chem. 268:1993;14991-14997
7. Ismailos G., Reppas C., Dressman J.B., Macheras P. Unusual solubility behaviour of cyclosporin A in aqueous media. J. Pharm. Pharmacol. 43:1991;287-289
8. Jiko M., Yano I., Wakasugi H., Saito H., Inui K. Evaluation of pharmacokinetic interaction between cyclosporin A and probucol in rats. Pharm. Res. 19. 2002;1362-1367
9. McMillan M.A. Clinical pharmacokinetics of cyclosporin. Pharmacol. Ther. 42:1989;135-156
10. Karlsson J., Kuo S.M., Ziemniak J., Artursson P. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br. J. Pharmacol. 110:1993;1009-1016
11. Kolars J.C., Stetson P.L., Rush B.D., Ruwart M.J., Schmiedlin-Ren P., Duell E.A., Voorhees J.J., Watkins P.B. Cyclosporine metabolism by P450IIIA in rat enterocytes-another determinant of oral bioavailability? Transplantation. 53:1992;596-602
12. Phung-Ba V., Warnery A., Scherman D., Wils P. Interaction of pristinamycin IA with P-glycoprotein in human intestinal epithelial cells. Eur. J. Pharmacol. 288:1995;187-192
13. Ryffel B., Woerly G., Greiner B., Haendler B., Mihatsch M.J., Foxwell B.M. Distribution of the cyclosporine binding protein cyclophilin in human tissues. Immunology. 72:1991;399-404
14. Sugimoto K., Sakamoto K., Fujimura A. Decrease in oral bioavailability of cyclosporin A by coadministration of probucol in rats. Life Sci. 60:1997;173-179
15. Sundararajan V., Cooper D.K., Muchmore J., Manion C.V., Liguori C., Zuhdi N., Novitzky D., Chen P.N., Bourne D.W., Corder C.N. Interaction of cyclosporine and probucol in heart transplant patients. Transplant. Proc. 23:1991;2023-2028
16. Tayrouz Y., Ding R., Burhenne J., Riedel K.-D., Weiss J., Hoppe-Tichy T., Haefeli W.E., Mikus G. Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. Clin. Pharmacol. Ther. 73:2003;397-405
17. Umehara K., Shimokawa Y., Miyamoto G. Effect of probucol on cytochrome P450 activities in human liver microsomes. Biol. Pharm. Bull. 25:2002;1112-1114
18. Wacher V.J., Wu C.Y., Benet L.Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13:1995;129-134
19. Wakasugi H., Yoshimoto M., Aoki M., Osawa R., Futami T., Ono T., Muso E., Inui K. Nippon. Jinzo. Gakkai. Shi. 43:2001;595-599
20. Wandel C., Kim R.B., Wood A.J.J., Stein C.M. "Inactive" ingredients may alter bioavailability of drugs through effects on P-glycoprotein (PGP) and CYP3A. Clin. Pharmacol. Ther. 69:2001;P71
21. Yang Z., Yonemochi E., Seki H., Yano K., Yamamoto K. Molecular interaction in solvents between pharmaceutical excipients and water insoluble drug (R)-1-[2, 3-dihydro-1-(2′-methylphenacryl)-2-oxo-5-phenyl-1H-1, 4-benzodiazepin-3-yl]-3-(3-methylphenyl) urea. Yakuzaigaku. 56:1996;224-231